Top

Published in:

01-01-2000

Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels

Authors: Mårten Fernö, Olle Stål, Bo Baldetrop, Thomas Hatschek, Ann-Christine Källström, Per Malmström, Bo Nordenskjöld, Stefan Rydén

Published in: Breast Cancer Research and Treatment | Issue 1/2000

Title: Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
Authors: Mårten Fernö
Olle Stål
Bo Baldetrop
Thomas Hatschek
Ann-Christine Källström
Per Malmström
Bo Nordenskjöld
Stefan Rydén
Publication date: 01-01-2000
Publisher: Kluwer Academic Publishers
Published in: Breast Cancer Research and Treatment / Issue 1/2000
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1023/A:1006332423620

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2000

Isolation of genes overexpressed in freshly isolated breast cancer specimens

The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy

The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast

Breast Cancer Research and Treatment

Course Announcement

Eradication of murine mammary adenocarcinoma through HSVtk expression directed by the glucose-starvation inducible grp78 promoter

Keynote webinar | Spotlight on antibody–drug conjugates in cancer